Sorrento Therpt Cmn (SRNE) 6.66 $SRNE Sorrento

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sorrento Therpt Cmn (SRNE) 6.66 $SRNE

Sorrento Therapeutics to Present at Two Upcoming Conferences in New York City
PR Newswire - Tue Aug 30, 3:01PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento", an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, and other unmet medical needs, announced today that it will be presenting at two upcoming conferences in New York City.
SRNE: 6.66 (+0.10)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Sorrento Therapeutics, Inc. - SRNE
ACCESSWIRE - Tue Aug 23, 8:29AM CDT
NEW YORK, NY / ACCESSWIRE / August 23, 2016 / Levi & Korsinsky announces it has commenced an investigation of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to:
SRNE: 6.66 (+0.10)

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sorrento Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Tue Aug 23, 6:11AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Sorrento Therapeutics, Inc. (NASDAQ: SRNE).
SRNE: 6.66 (+0.10)

Scintilla Pharmaceuticals, Inc., a Subsidiary of Sorrento Therapeutics, Inc., to Acquire Semnur Pharmaceuticals, Inc. to Further Deepen its Pain Management Pipeline
PR Newswire - Mon Aug 15, 5:34PM CDT
Scintilla Pharmaceuticals, Inc. ("Scintilla", a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento", has entered into a binding term sheet to acquire Semnur Pharmaceuticals, Inc. ("Semnur". Scintilla's lead program is resiniferatoxin ("RTX" for the treatment of intractable cancer pain.
SRNE: 6.66 (+0.10)

Commit To Buy Sorrento Therapeutics At $5, Earn 15.3% Annualized Using Options
StockOptionsChannel.com - Mon Aug 15, 10:33AM CDT
Investors eyeing a purchase of Sorrento Therapeutics Inc stock, but cautious about paying the going market price of $6.80/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
SRNE: 6.66 (+0.10)

Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene, to Join Sorrento as Chief Medical Officer and President of Clinical Development
PR Newswire - Mon Aug 15, 8:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento", an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, today announced that Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene Corporation (NASDAQ: CELG; "Celgene", has been appointed to the position of Chief Medical Officer and President of Clinical Development.
SRNE: 6.66 (+0.10), CELGZ: 1.16 (-0.03), CELG: 106.74 (unch)

Medovex Corp. Completes Financing Led by Sorrento Therapeutics, Inc.
Marketwire Canada - Tue Aug 09, 9:23AM CDT
ATLANTA, GA--(Marketwired - Aug 9, 2016) -  Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced the successful completion of a $1,150,000 financing transaction led by an investment from Sorrento Therapeutics, Inc. (NASDAQ: SRNE).
MDVX: 1.40 (-0.03), SRNE: 6.66 (+0.10)

Scintilla Pharmaceuticals, a Subsidiary of Sorrento Therapeutics, to Acquire SCILEX Pharmaceuticals to Add a Late-Stage Asset to Bolster its Pain Management Business
PR Newswire - Mon Aug 08, 8:00AM CDT
Scintilla Pharmaceuticals, Inc. ("Scintilla", a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento", has entered into a binding term sheet to acquire SCILEX Pharmaceuticals, Inc. ("SCILEX". Scintilla's lead program is resiniferatoxin ("RTX" for the treatment of intractable cancer pain.
SRNE: 6.66 (+0.10)

Sorrento to Form Joint Venture with CHA Biotech to Develop and Commercialize Natural Killer Cell Therapies
PR Newswire - Tue Aug 02, 8:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento", an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has entered into a binding term sheet to create a joint venture ("JV" with CHA Biotech Co. , LTD, (KOSDAQ: CHA; "CBT" of South Korea to develop and commercialize proprietary Chimeric Antigen Receptor ("CAR" modified cellular therapies based on CBT's Activated Killer Cell ("AKC" technology and five of Sorrento's CARs for all disease conditions, including oncology and infectious diseases. The JV covers products on a global basis with the exception of the Greater Chinese market.
SRNE: 6.66 (+0.10)

Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors
PR Newswire - Mon Aug 01, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento", an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today the appointment of Yue Alexander Wu, Ph.D to its Board of Directors (the "Board". Dr. Wu will also serve as a member of the Compensation Committee and Audit Committee of the Board. Doug Ebersole has resigned as a member of the Board for personal reasons.
SRNE: 6.66 (+0.10)

Sorrento Closes $150 Million Private Placement Investments
PR Newswire - Wed Jun 08, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento", an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs announced today that it has closed on $150 million related to the private placements of common stock and warrants previously announced by the company on April 4, 2016.
SRNE: 6.66 (+0.10)

Sorrento and 3SBio Announce CAR-T Joint Venture in China
PR Newswire - Tue Jun 07, 8:04AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento", an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today its subsidiary TNK Therapeutics, Inc. ("TNK" has entered into a joint venture agreement ("JVA" with Shenyang Sunshine Pharmaceutical Company Ltd ("3SBio" to develop and commercialize proprietary immunotherapies, including those developed from, including or using TNK's chimeric antigen receptor T cell ("CAR-T" technology targeting carcinoembryonic antigen ("CEA" positive cancers. 3SBio is a leading China-based biotechnology company focused on discovering, developing, manufacturing, and commercializing biopharmaceutical products.
SRNE: 6.66 (+0.10)

Sorrento Therapeutics to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu May 26, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento", an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that Dr. Henry Ji, President and CEO, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 in New York, NY. The Sorrento presentation is scheduled to begin at 9:00am EDT.
SRNE: 6.66 (+0.10)

Sorrento Announces Positive Data from a Combined Phase 2 & 3 Clinical Study of STI-004, an Anti-IgE Biosimilar Antibody
PR Newswire - Mon May 16, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento", an antibody-centric, clinical-stage biopharmaceutical company developing new therapies for cancer and other unmet medical needs announced that its partner, Mabtech Ltd., has successfully completed a combined Phase 2 & 3 clinical study in China for STI-004, a biosimilar antibody for Omalizumab (Xolair®). STI-004 met its primary endpoint in a multicenter, randomized, double-blind, placebo-controlled clinical trial.
SRNE: 6.66 (+0.10)

Wildcat Capital Issues Letter to Board of Sorrento Therapeutics
PR Newswire - Fri May 06, 8:00AM CDT
Wildcat Capital Management LLC ("Wildcat", whose clients hold an ownership stake of 6.5% of the common stock of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (the "Company" or "Sorrento", today sent a letter to the Company's Board of Directors (the "Board" urging the Board to take specific actions to remedy the ongoing destruction of significant shareholder value. In particular, the letter calls for the Board to immediately terminate and replace Dr. Henry Ji as Chief Executive Officer and to stop recently announced financing transactions to avoid further dilution to the existing shareholders. The letter also calls for the appointment of three Wildcat nominees to the Board to lead a special committee authorized to initiate a sales process for the Company.
SRNE: 6.66 (+0.10)

Sorrento closes private placement with Yuhan Corporation
PR Newswire - Mon May 02, 10:24AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento", an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has closed its previously announced private placement of common stock and warrants with Yuhan Corporation (000100.KS; "Yuhan" of South Korea for gross proceeds of $10 million.
SRNE: 6.66 (+0.10)

Sorrento to Present at 2 Upcoming Conferences in New York City
PR Newswire - Mon May 02, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Gunnar F. Kaufmann, Ph.D., Senior Vice President, Immunotherapy, & Head of Research and Global Partnerships, will present at 2 upcoming conferences in New York City:
SRNE: 6.66 (+0.10)

Sorrento to Present at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
PR Newswire - Thu Apr 14, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today 3 poster presentations at the upcoming AACR Annual Meeting 2016 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, USA, April 16 - 20, 2016.
SRNE: 6.66 (+0.10)

Sorrento to Present at the Jefferies Immuno-Oncology Summit
PR Newswire - Wed Apr 06, 11:53AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Gunnar F. Kaufmann, Ph.D., Senior Vice President, Immunotherapy, & Head of Research and Global Partnerships, will present at the Jefferies Immuno-Oncology Summit on Thursday, April 7, 2016 from 7:55 am to 8:20 am EDT. The conference will take place at the Boston Harbor Hotel in Boston, MA.
SRNE: 6.66 (+0.10)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 199

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 244

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 47

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 234

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 129

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 63

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 266

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 324

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating 50 Years: Mobil 1™ and Autodromo Partner Up

Updated Category News Views 237

Mobil 1™ Celebrates Milestone with Unique Autodromo Collaboration In a remarkable celebration of its 50-year anniversary, Mobil 1™, a pioneer in synthetic motor oil, has teamed up with Autodromo, renowned for its driving-inspired watches. This collaboration introduces the Mobil 1 Edition Monoposto, a limited-edition timepiece, showcasing their shared commitment to...

Continue Reading
diaMentis Introduces Innovative Breakthrough in Mental Health Diagnosis

Updated Category News Views 256

Advancements in Mental Health Diagnosis diaMentis, known for its forward-thinking diagnostic support technology, is making waves in the mental health sector by revealing groundbreaking results that enhance the diagnosis of mental illnesses. These findings not only signify a major breakthrough, but also represent a turning point for the company, enhancing its reputation in...

Continue Reading
CleanSpark's Impressive Growth: Achieving 30 EH/s in Hashrate

Updated Category News Views 77

CleanSpark's Breakthrough in Hashrate Efficiency CleanSpark Inc. (NASDAQ: CLSK), renowned as America's leading bitcoin miner, recently reached an operational hashrate of 30 EH/s (exahashes per second). This significant milestone reflects the company's remarkable growth and innovation in the competitive bitcoin mining industry. Transformative Growth through Strategic...

Continue Reading
Baidu's Bold Move: Aiming to Compete in Global Robotaxi Market

Updated Category News Views 108

Baidu's Ambitious Expansion Plans in Robotaxi Services Baidu Inc. is reportedly considering an exciting venture to extend its renowned robotaxi service, Apollo Go, into international markets. This bold decision follows a significant transition within the company as its CFO, Rong Luo, assumes a new role. Such developments signal Baidu's commitment to unlocking new avenues...

Continue Reading
Airship AI Secures Major Federal Contracts Amid Growing Demand

Updated Category News Views 198

Airship AI Achieves Significant Federal Contracts REDMOND, Wash. — Airship AI Holdings, Inc. (NASDAQ: AISP) is celebrating a remarkable accomplishment in the realm of public safety and security. The company has recently secured 16 individual contracts from various federal law enforcement agencies, highlighting the ongoing relevance and necessity of AI technologies in...

Continue Reading